Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.81 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | KRAS | P01116 | 4/20 | 0.73 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.66 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.65 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.65 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.65 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.65 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.65 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172347 | 1.00 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RY6 | |
| Guanosine Triphosphate SCHEMBL20578209 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| Guanosine Triphosphate SCHEMBL20302658 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL28850747 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL28353381 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| Guanosine Triphosphate SCHEMBL27989290 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL28001538 | 0.99 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL23969756 | 0.99 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL18785111 | 0.99 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RY6 | |
| SCHEMBL101367 | 0.99 | TGM2 (0.82) | TGM2NT5EKRASFUT5P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113101908-A | Hybrid ligand hierarchical pore metal organic framework material and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4358953-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240082218-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| CN-117618654-A | Antibacterial angiogenesis-promoting nylon6 material and preparation method thereof | 中维化纤股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240066009-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | Sanford Burnham Prebys Medical Discovery Institute | 2024-02-29 | — | — | US | disclosed |
| CN-117529314-A | Pharmaceutical combinations comprising KRAS G12C inhibitors and their use for the treatment of cancer | 诺华股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | MODERNATX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4267134-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO., INC. | 2006-12-28 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1599469-B1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1599469-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005044816-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | TGM2 438/4885NT5E 1538/4885KRAS 3888/4885 |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | HCAR1, HCAR2, FFAR1 | TGM2 3239/4885NT5E 368/4885KRAS 3148/4885 |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | TGM2 438/4885NT5E 1538/4885KRAS 3888/4885 |
| US-20240066009-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | CRHBP, GRIN2C, GRIN2B | TGM2 2149/4885NT5E 2689/4885KRAS 4419/4885 |
| US-20240082218-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS | KRAS, NRAS, PTPN1 | TGM2 1842/4885NT5E 2830/4885KRAS 1/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TGM2 1032/4885NT5E 2539/4885KRAS 3049/4885 |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, CPSF7 | TGM2 3089/4885NT5E 375/4885KRAS 2731/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | TGM2 767/4885NT5E 9/4885KRAS 2465/4885 |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TGM2 1032/4885NT5E 2539/4885KRAS 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.